Actualités

ABBV's Skyrizi and Rinvoq post strong Q1 growth, lift 2026 sales outlooks and sustain momentum through new indications.

Rare Autoimmune Disease Could Become New Growth Opportunity

With the rate environment stabilizing in mid-2026, income investors are circling back to a familiar playbook: own the businesses that have raised payouts through every cycle in living memory. Dividend Kings and Aristocrats with 25-plus years of consecutive hikes offer a growing cash payment backed by durable franchises that the bond market still struggles to ... 3 No-Brainer Dividend Growth Stocks to Buy in June

Johnson & Johnson (NYSE:JNJ) has announced positive findings from its Phase 2/3 ENERGY clinical trial, with IMAAVY (nipocalimab-aahu) demonstrating statistically significant improvements in hemoglobin levels among patients with warm autoimmune hemolytic anemia compared with placebo. The results provide further support for the therapy as the company seeks regulatory approval for a condition that currently has no FDA-approved treatment options.

As medtech companies eye entry into the IVL space, Shockwave Medical is consolidating its position through innovation and ongoing data generation.

A retired couple with a $2 million dividend-focused portfolio yielding roughly 6%, or $120,000 per year, watched their income stream fall by $14,400 during a difficult market period as covered-call funds, mortgage REITs, and business development companies trimmed distributions. Their annual income dropped to $105,600. They did not sell a share. Understanding why they were ... A $2 Million Dividend Portfolio Cut Its Distribution by $14,400 in One Year and the Holders Did Not Sell

Intravascular lithotripsy (IVL) has experienced strong uptake since Shockwave Medical became the first to market in the space.

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) said it has activated the first clinical site for its first-in-patient POLB 001 TOPICAL trial, moving its lead cancer immunotherapy programme into patient recruitment as interim data remains on track for summer 2026. The AIM-listed company...

Johnson & Johnson (JNJ) is one of the biggest names in health care, and lately, its stock has been living up to the hype. Shares have climbed back toward record territory, while much of the market has been affected by a sharp sell-off in technology stocks. Now, the company is pumping fresh cash ...

Healthcare stocks fell late Wednesday afternoon with the NYSE Healthcare Index declining 0.8% and th

A Los Angeles jury found Johnson & Johnson (NYSE:JNJ) and its subsidiaries liable in a talc trial linked to mesothelioma. The jury awarded US$32 million to the family of a woman whose fatal illness was tied to long term use of the company’s talc based baby powder. The verdict adds to ongoing legal and reputational pressure surrounding historical talc products and alleged asbestos contamination. Johnson & Johnson, a diversified healthcare company with pharmaceuticals, medical devices, and...

I keep buying NVIDIA, Eli Lilly, and Johnson & Johnson, and if a fire took my brokerage statement to zero tomorrow, those are the three tickers I would start typing in again on day one. They each do something I cannot replicate by being clever. Why the buy button stays active on NVIDIA NVIDIA (NASDAQ:NVDA) ... I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow

Ten thousand dollars a month in dividend income works out to $120,000 per year. That is enough to cover the rent on a luxury waterfront condo in Miami Beach, one of the most expensive rental markets in the country. The math that gets you there is simple: $120,000 divided by your portfolio yield equals the ... The Portfolio That Gets You a Waterfront Condo in Miami Beach

Johnson & Johnson (NYSE:JNJ) is a rare long-duration compounder because it is the rare equity whose credit quality, dividend record, and demand profile collectively rival a sovereign bond while still compounding capital. Healthcare is the one expense Americans cannot defer, and Johnson & Johnson sits at the center of how that spending gets delivered. Pillar ... Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond

Johnson & Johnson (NYSE:JNJ) was among the stocks Jim Cramer discussed on Mad Money, along with the recent sell-off in the market. Cramer was bullish on the stock during the episode, as he said: Now, you can make good money for a while if you go all in on what’s hot, but I never do […]

A $35,000 annual income is roughly comparable to the Social Security benefits many retired couples receive each year. It is also about what a $1 million portfolio can generate when invested in dividend growth names like Johnson & Johnson (NYSE:JNJ), Coca-Cola (NYSE:KO), Procter & Gamble (NYSE:PG), and broad dividend ETFs. The interesting question is not ... The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep

Joaquin Duato said AI was already helping the company develop medicines faster, but the extent to which it boosts its bottom line has yet to be seen.

ChatGPT breaks down how retirees generate $2,000 monthly passive income in 2026 from dividends, bonds, REITs, rentals and annuities with capital needed.

Johnson & Johnson agreed to acquire Firefly Bio for $1 billion in a move to expand its oncology pipeline. The deal adds degrader-antibody conjugate technology focused on KRAS-driven cancers to Johnson & Johnson's research efforts. The acquisition is aimed at strengthening Johnson & Johnson's position in cancer therapeutics beyond its existing portfolio. For investors tracking NYSE:JNJ, this acquisition comes with the stock at a share price of $232.16 and multi-year returns that have been...

Nvidia, Visa and Microsoft lead the list of Wall Street's top Dow Jones stocks to buy now. Some other names might surprise you.

A 65-year-old retiree with $1 million who follows the standard 4% rule withdraws $40,000 in the first year, then increases that amount over time to keep pace with inflation. A dividend-focused alternative starts slightly lower, at about $38,000 in annual income from a 3.8% blended yield, but does not require selling shares. Over 20 years, ... The Dividend Strategy That Beats the 4% Rule by $400,000 Over 20 Years on a $1 Million Portfolio

JNJ is set to acquire Firefly Bio for $1 billion in cash, adding its Firelink DAC platform and advancing efforts in KRAS-driven cancer treatments.

J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.

In recent weeks, Johnson & Johnson reported positive late‑stage data and regulatory milestones across multiple therapies, including TECVAYLI in relapsed/refractory multiple myeloma, amivantamab-based regimens in lung and head and neck cancers, and a TREMFYA label update in psoriatic arthritis. These advances, alongside progress for nipocalimab in systemic lupus erythematosus and Sjögren's disease and expanded frontline use of Darzalex in the UK, highlight how Johnson & Johnson is broadening...

Johnson & Johnson (NYSE:JNJ) has rallied 13.73% year to date and 55.27% over the past year, fueled by oncology blockbusters and a MedTech franchise hitting on every cylinder. CEO Joaquin Duato told investors that “Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth ... Will Johnson & Johnson Stock Hit $300 This Year?

Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.

Tango Therapeutics shares rallied on Monday after recording impressive results for its pancreatic cancer drug. Here’s how you should play TNGX stock at current levels.

A $1.2 million portfolio generating $7,200 per month produces $86,400 in annual income, equivalent to a blended yield of 7.2%. According to the Social Security Administration’s 2026 COLA fact sheet, the average aged couple receiving Social Security benefits collects about $3,208 per month, or $38,496 per year. That means a portfolio generating $7,200 per month ... A Portfolio That Doubles Your Social Security Check—and Your Spouse’s

The transaction is expected to close later this year, subject to regulatory approvals and other customary closing conditions.

NICE has preliminarily recommended D-VRd for NHS use as a first-line treatment for transplant-ineligible multiple myeloma.